Sweden's Kosan Biosciences says that preliminary results of a Phase I trial of its experimental heat shock protein 90 inhibitor showed signs of antiocancer activity and tolerability. Several biotechs are racing to develop Hsp90 inhibitors, including Infinity Pharmaceuticals, which researchers believe will ultimately lead to a treatment that can kill of cancer cells. Release